phonecontact
cards

Category: General - Part 5

Oasmia Looks To Duplicate Success With A Validated Model

Last month I wrote a detailed article introducing investors to Oasmia Pharmaceuticals (NASDAQ:OASM), a Swedish-based biopharmaceutical company developing next-generation novel formulations of well-established chemotherapeutic agents through its proprietary nanotechnology platform. Shares of Oasmia are up 50% since that article, and I think the upward momentum in the stock will continue based on some recent positive…

How BioSig Technologies Is Positioned To Change the Electrophysiology Market

BioSig Technologies, Inc. (BSGM) is a Minnesota-based medical device company developing a proprietary technology platform designed to improve the rapidly growing multi-billion dollar electrophysiology (EP) marketplace. The company’s leading product is Pure EP™, a surface electrocardiogram (EKG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists during catheter ablation procedures to treat cardiac…

SRNT Abstracts on SPECTRUM® Cigarettes Show Potential Market Opportunity For 22nd Century Group

The Society for Research on Nicotine & Tobacco (SRNT) held its Annual Meeting in Chicago, IL on March 2-5, 2016. At that meeting, 15 independently conducted scientific studies with SPECTRUM® Cigarettes were presented in oral presentation or poster form. SPECTRUM® is a brand of “research cigarette” commissioned by the National Institute on Drug Abuse (NIDA), along with…

Oasmia Pharmaceuticals – Advancing Nanotechnology Based Chemotherapies

Oasmia Pharmaceuticals AB (NASDAQ: OASM) is a Swedish-based biopharmaceutical company developing next-generation novel formulations of well-established chemotherapeutic agents through its proprietary nanotechnology platform. Compared to existing cytostatic agents, Oasmia’s improved formulations offer reduced side-effects, potentially leading to expanded therapeutic use, as well as reduced infusion time, better pharmacologic profile, and superior bioavailability. The lead product…

RedHill Biopharma Packed With Catalysts In 2016

On February 25, 2016, RedHill Biopharma Ltd. (RDHL) reported financial results for the fourth quarter and full year ending December 31, 2015. The company also hosted a conference call with investors to highlight the operational results from 2015 and provide an update on the late-stage pipeline. There are a tremendous number of catalysts for RedHill…

Fourth Quarter Results Show What’s To Come For 22nd Century Group

On February 18, 2016, 22nd Century Group, Inc. (NYSE MKT: XXII) filed its Form 10K annual report for the year ending December 31, 2015. Early this morning the company held a conference call to provide an update for shareholders. Given that the company’s two key cigarette brands, MAGIC® and RED SUN®, are still in the early stages…

RHB-105: The Medical Market Perspective (Part 1)

One of the most advanced clinical-stage candidates at RedHill Biopharma Ltd (RDHL) is RHB-105, a new triple combination therapy for the eradication of H. pylori infection in humans. RedHill has successfully completed a Phase 3 clinical trial with RHB-105, reporting positive results in June 2015 from the ERADICATE-Hp study. ERADICATE-Hp was a randomized, double-blind, placebo-controlled…

Buy This Pharma Company To Get Another Completely Free!

How Nuvo Research Splitting Into Two Companies Is A Win-Win For Shareholders Last week, Nuvo Research Inc. (NRI.TO) mailed a Management Information Circular to shareholders explaining the impetus and logistics for the planned separation of the company into two separately traded entities, a specialty pharmaceutical business to be called Nuvo Pharmaceuticals Inc., and a drug development…

22nd Century Working With FDA On Modified Risk Cigarette

Earlier in January, I  alerted investors to the fact that 22nd Century Group (NYSEMTK: XXII) filed an MRTP application to the U.S. FDA for Brand-A, a code name for the company’s modified risk very low nicotine (VLN) cigarette that contains roughly 95% less nicotine per cigarette versus commercially available brands. MRTP stands for Modified Risk Tobacco Product,…

Update On BriaCell Therapeutics Following Meeting With CEO

Last week in San Francisco, I had a good talk with Joseph P. Wagner, PhD, the CEO of BriaCell Therapeutics (BCT.V / BCTXF). He provide a good update on the current situation, which I report to investors in this article. Right now, the company’s is in active preparation to begin the Phase 2 trial, with…